Skip to content
Open access

Long-Term Efficacy of Adjunctive Cenobamate by Focal Seizure Subtypes: Open-Label Extension of a Randomized Clinical Study in a Multinational Asian Population.

Nov 2026 · Neurological Therapeutics · 0 citations · 19 references
Medicine

Abstract

INTRODUCTION To evaluate adjunctive cenobamate efficacy by focal seizure subtype during the open-label extension (OLE) of a phase 3 randomized, double-blind, placebo-controlled study (C035) in Asian patients with focal seizures.

Methods

Patients aged 18-70 years old with uncontrolled focal seizures despite treatment with 1-3 antiseizure medications who completed the double-blind study (n = 425) could enter the 52-week OLE, comprising a 20-week blinded conversion from placebo or 100, 200, or 400 mg/day cenobamate to a target cenobamate dose of 400 mg/day before entering a 32-week open-label maintenance phase at 300 mg/day. Percent change from double-blind baseline in 28-day seizure frequency and responder rates (e.g., ≥ 50% reduction from baseline) for focal preserved consciousness with observable manifestations (FPC), focal impaired consciousness (FIC), or focal to bilateral tonic-clonic (FBTC) seizure subtypes were assessed in the open-label maintenance phase efficacy population (OLE-EM, ≥ 1 dose of study drug and any seizure data during the open-label maintenance phase). Safety and tolerability were assessed.

Results

Among patients who entered the OLE, 357/410 (263 originally randomized to cenobamate; 94 who converted from placebo to cenobamate) were included in the OLE-EM population. Median percent seizure frequency reductions were 84.5% for FPC (n = 65), 83.0% for FIC (n = 301), and 100% for FBTC (n = 94) in the OLE-EM population. For FPC, FIC, and FBTC subtypes, ≥ 50% responder rates were 75.4%, 73.8%, and 84.0%, respectively, and 100% responder rates were 23.1%, 28.2%, and 58.5%. Among patients entering the OLE, 84.6% (347/410) completed the 52 weeks of treatment with cenobamate. The most common treatment-emergent adverse events were dizziness, somnolence, gamma-glutamyl transferase increased, and COVID-19 infection.

Conclusions

During the C035 OLE maintenance phase, high seizure frequency reductions were seen for FPC, FIC, and FBTC focal seizure subtypes. Cenobamate was generally well tolerated, and the results were consistent with the double-blind treatment study. Graphical abstract available for this article. TRIAL REGISTRATION NCT04557085 (registered September 14, 2020).

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.